PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization
Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges TOKYO , Oct. 5, 2026 /PRNewswire/ -- ...
2026-10-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Energenesis Biomedical and Yoo Young Pharm Sign MOU for ENERGI-F703DFU Development and Commercialization in Korea
TAIPEI , Oct. 5, 2026 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ...
2026-10-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
From Run Clubs to the Nation: ELDON partners with KBS to extend the Spirit of "Wellness On and On" to Hari Sukan Negara 2026
Malaysian health and wellness brand ELDON partners with Ministry of Youth and Sports Malaysia (KBS) to bring its "Wellness On and On" movement from local running clubs to a national platform ...
2026-10-05T    Health Care/Hospital   Sports 
EVIDENT Completes Acquisition of CrestOptics S.p.A.
NEEDHAM, Mass. , Oct. 5, 2026 /PRNewswire/ -- Evident announced today that it has completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging ...
2026-10-05T    Biotechnology   Computer/Electronics   Electronic Components   Health Care/Hospital 
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care ...
2026-10-05T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
The only known investigational therapy for SBMA in Phase 3 development worldwide ...
2026-10-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
MH WellFest Cambodia 2026 Marks a New Chapter in ASEAN Healthcare Connectivity
PHNOM PENH, Cambodia , Oct. 5, 2026 /PRNewswire/ -- Maybank (Cambodia) Plc. and the Malaysia Healthcare Travel Council (MHTC) have concluded MH WellFest Cambodia 2026 at Borey Peng Huoth Eco ...
2026-10-05T    Banking/Financial Service   Health Care/Hospital   Medical/Pharmaceuticals   Travel 
Celaid Therapeutics Completes Second Close of Series B Financing Round
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate  U.S. Clinical Trial Preparations for CLD-001 ...
2026-10-05T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared ...
2026-10-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
MILAN , Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with ...
2026-10-04T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.